{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:07:14Z","timestamp":1789150034767,"version":"build-2803163510"},"reference-count":48,"publisher":"BMJ","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2026,8,31]]},"DOI":"10.1136\/ejhpharm-2026-005172","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:20:47Z","timestamp":1789147247000},"page":"ejhpharm-2026-005172","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Excreta contamination after antibody\u2013drug conjugates administration: a systematic review and guidance for hospital pharmacists"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2285-781X","authenticated-orcid":false,"given":"Roland B","family":"van den Berg","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC, location Vrije Universiteit, Amsterdam, The Netherlands"},{"name":"Department of Hospital Pharmacy, Groene Hart Ziekenhuis, Gouda, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Bonte","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC, location Vrije Universiteit, Amsterdam, The Netherlands"},{"name":"Department of Hospital Pharmacy, AZ Sint-Lucas Brugge, Bruges, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L","family":"Niggebrugge-Mentink","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Haga Teaching Hospital, The Hague, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina W","family":"Swart","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora L","family":"Swart","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC, location Vrije Universiteit, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Crul","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC, location Vrije Universiteit, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"2026091110202527000_ejhpharm-2026-005172v1.1","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0b013e3181f72b63"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.2","unstructured":"European Union . Guidance for the safe management of hazardous medicinal products at work. 2023."},{"key":"2026091110202527000_ejhpharm-2026-005172v1.3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/15459624.2020.1776299","article-title":"Occupational exposure of pharmacy technicians and cleaning staff to cytotoxic drugs in Dutch hospitals","volume":"17","author":"Crul","year":"2020","journal-title":"J Occup Environ Hyg"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.4","unstructured":"European Parliament and the Council of the European Union . Directive 2004\/37\/EC of the European Parliament and of the Council of 29 April 2004 on the protection of workers from the risks related to exposure to carcinogens or mutagens at work (Sixth individual Directive within the meaning of Article 16(1) of Counc. 2022. Available: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=celex%3A32004L0037 [Accessed 20 May 2024]."},{"key":"2026091110202527000_ejhpharm-2026-005172v1.5","unstructured":"Stichting Arbeidsmarkt Ziekenhuizen (StAZ) . Arbocatalogus Beter met Arbo. 2026. Available: https:\/\/betermetarbo.nl\/ [Accessed 27 Mar 2026]."},{"key":"2026091110202527000_ejhpharm-2026-005172v1.6","unstructured":"UMCNL . Dokterhoe \u2013 Safe and healthy working information for UMC staff. 2026. Available: https:\/\/www.dokterhoe.nl\/ [Accessed 27 Mar 2026]."},{"key":"2026091110202527000_ejhpharm-2026-005172v1.7","doi-asserted-by":"publisher","DOI":"10.1177\/1078155212459667"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.8","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1177\/1078155216637217","article-title":"Safe handling of oral antineoplastic medications: Focus on targeted therapeutics in the home setting","volume":"23","author":"Cass","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3835(88)90011-0"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.10","doi-asserted-by":"publisher","DOI":"10.1080\/00039896.1996.9936030"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.11","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199426050-00004"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.12","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200606000-00015"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.13","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686315"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.14","unstructured":"National Institute for Occupational Safety and Health . NIOSH alert: preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. Cincinnati, OH, 2004."},{"key":"2026091110202527000_ejhpharm-2026-005172v1.15","first-page":"1957","article-title":"Guidelines for the safe handling of excreta contaminated by cytotoxic agents","volume":"49","author":"Cass","year":"1992","journal-title":"Am J Hosp Pharm"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.16","doi-asserted-by":"publisher","DOI":"10.1080\/03602530600952172"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.17","first-page":"S11","article-title":"Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future","volume":"57 Suppl 10","author":"Vezina","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.18","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.068049"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.19","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214550729"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.20","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/1078155217698846","article-title":"Safe handling of monoclonal antibodies: Too large to be hazardous?","volume":"24","author":"de Lemos","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.21","doi-asserted-by":"publisher","DOI":"10.2165\/11531280-000000000-00000"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.22","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody\u2013drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"The Lancet"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.23","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-015-1657-7"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.24","unstructured":"Wells G , Shea B , O\u2019Connell D , et al . n.d. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available: https:\/\/ohri.ca\/en\/who-we-are\/core-facilities-and-platforms\/ottawa-methods-centre\/newcastle-ottawa-scale"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.25","doi-asserted-by":"publisher","DOI":"10.2174\/138920012802138598"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.26","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.116"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.27","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2018.1531158"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.28","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2020.1755909"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.29","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3390\/jcm10061323","article-title":"Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY\u00ae) Antibody\u2013Drug Conjugate in Sprague Dawley Rats","volume":"10","author":"Yip","year":"2021","journal-title":"JCM"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.30","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.5599\/admet.2582","article-title":"Preclinical pharmacokinetics, distribution, metabolism and excretion of disitamab vedotin","volume":"13","author":"Wang","year":"2025","journal-title":"ADMET DMPK"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.31","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12224"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.32","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/00498254.2024.2336576","article-title":"A general perspective for the conduct of radiolabelled distribution, metabolism, and excretion studies for antibody-drug conjugates","volume":"54","author":"Rudolph","year":"2024","journal-title":"Xenobiotica"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.33","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/ceat.201800476","article-title":"Life Cycle Optimization for Synthetic Rubber Glove Manufacturing","volume":"42","author":"Poh","year":"2019","journal-title":"Chem Eng Technol"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.34","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00280-021-04250-0","article-title":"Clinical pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology","volume":"87","author":"Liu","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.35","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-014-1584-z"},{"key":"2026091110202527000_ejhpharm-2026-005172v1.36","unstructured":"European Medicines Agency . Blenrep : EPAR \u2013 Product information (Summary of product characteristics, Annex I). 2025. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/blenrep [Accessed 22 Feb 2026]."},{"key":"2026091110202527000_ejhpharm-2026-005172v1.37","unstructured":"European Medicines Agency . Adcetris: EPAR - Product information (Summary of product characteristics, Annex I). 2012. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/adcetris [Accessed 08 Apr 2026]."},{"key":"2026091110202527000_ejhpharm-2026-005172v1.38","unstructured":"European Medicines Agency . Datroway : EPAR \u2013 Product information (Summary of product characteristics, Annex I). 2025. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/datroway [Accessed 22 Feb 2026]."},{"key":"2026091110202527000_ejhpharm-2026-005172v1.39","unstructured":"European Medicines Agency . Padcev : EPAR \u2013 Product information (Summary of product characteristics, Annex I). 2022. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/padcev [Accessed 22 Feb 2026]."},{"key":"2026091110202527000_ejhpharm-2026-005172v1.40","unstructured":"European Medicines Agency . Mylotarg : EPAR \u2013 Product information (Summary of product characteristics, Annex I). Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mylotarg [Accessed 22 Feb 2026]."},{"key":"2026091110202527000_ejhpharm-2026-005172v1.41","unstructured":"European Medicines Agency . Besponsa : EPAR \u2013 Product information (Summary of product characteristics, Annex I). 2017. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/besponsa [Accessed 22 Feb 2026]."},{"key":"2026091110202527000_ejhpharm-2026-005172v1.42","unstructured":"European Medicines Agency . Zynlonta : EPAR \u2013 Product information (Summary of product characteristics, Annex I). 2022. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zynlonta [Accessed 22 Feb 2026]."},{"key":"2026091110202527000_ejhpharm-2026-005172v1.43","unstructured":"European Medicines Agency . Elahere : EPAR \u2013 Product information (Summary of product characteristics, Annex I). 2024. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elahere [Accessed 22 Feb 2026]."},{"key":"2026091110202527000_ejhpharm-2026-005172v1.44","unstructured":"European Medicines Agency . Polivy: EPAR - Product information (Summary of product characteristics, Annex I). 2020. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/polivy [Accessed 08 Apr 2026]."},{"key":"2026091110202527000_ejhpharm-2026-005172v1.45","unstructured":"European Medicines Agency . Trodelvy : EPAR \u2013 Product information (Summary of product characteristics, Annex I). 2021. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/trodelvy [Accessed 22 Feb 2026]."},{"key":"2026091110202527000_ejhpharm-2026-005172v1.46","unstructured":"European Medicines Agency . Tivdak : EPAR \u2013 Product information (Summary of product characteristics, Annex I). 2025. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tivdak [Accessed 22 Feb 2026]."},{"key":"2026091110202527000_ejhpharm-2026-005172v1.47","unstructured":"European Medicines Agency . Enhertu: EPAR - Product information (Summary of product characteristics, Annex I). 2021. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/enhertu [Accessed 08 Apr 2026]."},{"key":"2026091110202527000_ejhpharm-2026-005172v1.48","unstructured":"European Medicines Agency . Kadcyla: EPAR - Product information (Summary of product characteristics, Annex I). 2013. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kadcyla [Accessed 08 Apr 2026]."}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2026-005172","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:20:59Z","timestamp":1789147259000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2026-005172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":48,"alternative-id":["10.1136\/ejhpharm-2026-005172"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2026-005172","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]}}}